Kornimate/medical-research-clean huggingface dataset:
dehydroepiandrosterone (dhea) intervention to treat ovarian aging

Conditions: Infertility; Ovarian Aging; Diminished Ovarian Reserve (DOR); Predicted Poor-responders

Summary: * to test the hypothesis that supplementation of dhea for at least twelve weeks prior to and during ovarian stimulation increases oocyte quantity (number of oocytes retrieved) and oocyte quality (clinical pregnancy rates and molecular markers) following ivf and ivf/icsi treatment. * to evaluate the feasibility of conducting a large multicentre trial

the purpose of this study is to evaluate the role of dhea in counteracting the effects of ovarian ageing in an in-vitro fertilization (ivf) model. the study will examine whether the use of dhea could improve clinical pregnancy rates following ivf treatment in women predicted to have aged ovaries by increasing oocyte quantity (ovarian response to gonadotrophins) and/ or by improving oocyte quality. the oocyte quality will be assessed by morphological and molecular markers. this study will provide a mechanistic framework for translational research on mechanisms of ovarian ageing and drug interventions to slow down the ovarian ageing process and subsequent adverse physical and psychological consequences. further, the data that will be produced from this research will have the potential to influence clinical practice in fertility clinics worldwide.

Eligibility criteria:
inclusion criteria: * women aged above 23 years with diminished ovarian reserve (predicted to be poor-responder), defined as antral follicle count \<10 and/or anti-mullerian hormone \<5pmol/l * women undergoing ivf and ivf/icsi treatment * women must have a regular spontaneous menstrual cycle of 21 - 35 days exclusion criteria: * women with bmi \>35 kg/m2 * women with a single ovary * women with untreated hydrosalpinx/ submucous fibroid/ endometrial polyp at the start of treatment * women with any history of seizure disorders * women with previous participation in this trial in an earlier treatment cycle * women with any known endocrine disorders such as congenital adrenal hyperplasia, thyroid diseases, hyperprolactinemia * known allergy to dhea * diabetic women on insulin as insulin lowers dhea levels and might reduce the effectiveness of dhea supplements.
viatorr cx case-control study for complications of portal hypertension

Conditions: Liver Cirrhoses; Portal Hypertension

Summary: to evaluate the clinical benefits in the patients receiving viatorr cx over a period of 12 months of structured follow-up (before tips, at tips, 1 week after tips, at 6 weeks, 4 months, 6 months, 9 months, 12 months), regarding clinical endpoints, such as he, readmission, liver injury, cardiac function, response to tips and the passive expansion of the stents in real life.

case-control study using the patients in the university clinic bonn receiving viatorr cx (n=40), using a comparison ration 1:1:1 to viatorr and bare metal stents. of these patients, 20 patients will receive viatorr cx and the assessement of the width of the stent as outlined in the jvir-paper published this year. the viatorr and bms controls with similar age, gender, child, meld and indication for tips. a total of 125 patients with the primary composite-endpoint he/readmission will be investigated secondary endpoints are liver injury, cardiac function, response to tips and the passive expansion of the stents in real life.

Eligibility criteria:
inclusion criteria: * patients suitable for tips exclusion criteria: * contraindication for tips
brief behavioral intervention for dyspnea in patients with advanced lung cancer

Conditions: Lung Cancer

Summary: this research study is evaluating a behavioral intervention designed to help people with advanced lung cancer manage dyspnea (i.e., breathlessness or shortness-of-breath).

many individuals with advanced lung cancer experience debilitating breathlessness at some point during the course of their illness. unfortunately, few interventions exist to treat this distressing symptom of cancer. the purpose of this study is to test the efficacy of a brief behavioral intervention may help relieve breathlessness in individuals with advanced lung cancer. participants will have a 50/50 chance of receiving the behavioral intervention or standard care. the principal investigator of the study, dr. joseph greer, is a licensed clinical psychologist who has trained oncology nurses in how to deliver the behavioral intervention. the oncology nurses will meet with participants during their outpatient oncology appointments, such as chemotherapy infusions, to review the behavioral skills that may help with breathlessness. this intervention involves no medications but rather teaches patients skills for breathing control and relaxation of the body.

Eligibility criteria:
inclusion criteria: * a diagnosis of either nsclc, sclc, or mesothelioma, not being treated with curative intent * self-reported shortness of breath (a score of 2 or greater on the modified medical research council dyspnea scale) * eastern cooperative oncology group (ecog) performance status from 0 (asymptomatic) to 2 (symptomatic and in bed \<50% of day) * the ability to read and respond to questions english * primary cancer care at the massachusetts general hospital (mgh) cancer center or dana-farber cancer institute (dfci) * age \>18 years exclusion criteria: * cognitive or psychiatric conditions prohibiting study consent or participation. * a treating clinician who reports that the patient is inappropriate for the study

Keywords: lung cancer
the global cardiovascular risk consortium

Conditions: All-cause Mortality; Cardiovascular Disease

Summary: the global cardiovascular risk consortium (gcvrc) brings together harmonized individual-level data from over 2 million individuals across 133 cohorts, 39 countries, and 6 continents, with recruitment ongoing. the gcvrc examines the impact of classical cardiovascular risk factors-such as body mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes-on cardiovascular disease (cvd) and death from any cause worldwide.

a small number of modifiable risk factors may account for a significant proportion of cardiovascular disease (cvd) risk. however, the cvd burden attributable to classical risk factors depends on the populations studied and the methodologies used. the global cardiovascular risk consortium (gcvrc) is an international collaboration that continuously includes cohort studies from around the world to improve cardiovascular risk prediction. the gcvrc uses extensively harmonized individual-level data from currently more than 2 mio individuals from 133 cohorts, 39 countries and 6 continents categorized in 8 geographical regions (based on a modification of who and united nations definitions) - north america, latin america, sub-saharan africa, north africa and the middle east, western europe, eastern europe and russia, asia, and oceania. the consortium has a special focus on classical, potentially modifiable cardiovascular risk factors: body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes. key research questions include examining the impact of these factors on major outcomes by geographical region and sex, as well as estimating associated lifetime risk and the potential lifetime difference when modifying these risk factors. this work is critical for developing regionally tailored cvd prevention and treatment strategies, identifying residual risk, and improving global cardiovascular health. based on gcvrc data, a landmark paper on the effect of classical risk factors on new-onset cvd and all-cause mortality was published in the new england journal of medicine in 2023 (https://doi.org/10.1056/nejmoa2206916).

Eligibility criteria:
inclusion criteria: population-based individual-level data with available information on the classical cardiovascular risk factors including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes, as well as the outcomes of interest. exclusion criteria: * participants with age below 18 years * no information on the outcome of interest * no information on the exposure of interest (cvd risk factors) * history of cvd at baseline

Keywords: cardiovascular disease cardiovascular risk factors risk factor modification global lifetime gain
survey about stress-covid in health care workers in north africa country

Conditions: HEALTH CARE WORKERS

Summary: this study aimed to investigate the psychological impact of the covid-19 outbreak on healthcare workers (hcws) and to identify ways of coping with this unprecedented stressful situation.

this was a cross-sectional study based on an online questionnaire that included 62 questions (scores, 0 - 3). the chi-square (χ²) test was used to compare the responses between professional groups, age groups, and genders.

Eligibility criteria:
inclusion criteria: * health care workers exclusion criteria: * no one
physiologic study of cerebral perfusion

Conditions: Cerebral Perfusion Pressure; Vasopressor Agents; Shock; Magnetic Resonance Imaging (MRI), Functional

Summary: the aim of the study is to measure cerebral perfusion using mri in healthy subjects (with and without sedation) and in vasopressor-dependent patients


Eligibility criteria:
healthy subjects : * inclusion criteria : * being over 18 years old * exclusion criterias : * having a positive serum pregnancy test * having a contraindication to mri * having a contraindication to receive light sedation with propofol * suffering of claustrophobia or of anxiety disorder shock subjects : * inclusion criterias : * being over 18 years old * being hospitalized to the medical intensive care unit of the chus fleurimont * being in a stabilized shock state, primarily of distributive etiology * having received an appropriate fluid resuscitation, as judged by the attending physician * exclusion criterias : * having a different primary etiology of shock than distributive (cardiogenic, hypovolemic, obstructive) * needing vasopressor therapy as the result of extracorporeal circulation * having known cerebral lesions * having an intra-aortic balloon pump * being in a palliative or near end-of-life situation * having a contraindication to mri * suffering of claustrophobia or of anxiety disorder
evaluating the safety of donepezil hydrochloride (aricept) for up to 1 year in the treatment of the cognitive dysfunction exhibited by children with down syndrome - follow-up to a 10-week, double-blind, placebo-controlled trial

Conditions: Down Syndrome

Summary: the purpose of this study is to determine the safety of donepezil hydrochloride (aricept) in children with down syndrome who have finished the preceding 10-week, double-blind study of donepezil hydrochloride. medical tests for drug safety will be conducted at each clinic visit.

all children in this study will take donepezil hydrochloride once a day, and will come back to the clinic at 8, 24 and 42 weeks after the study has begun. in between these clinic visits, the clinical staff will telephone the child's parent or caregiver to discuss drug safety observations and possible changes in drug dose. at the end of the study (42 weeks), psychological testing will also be given to determine how well the child is functioning.

Eligibility criteria:
inclusion criteria: * diagnosis of down syndrome (established during study e2020-a001-220). * completion of study e2020-a001-219 (nct00570128 \[also known as a2501059\]) with no ongoing seroius adverse events and no severe drug reactions. exclusion criteria: * weight less than 20 kg. * clinically significant conditions affecting absorption, distribution or metabolism of the study medication. * no reliable parent or caregiver, or unwillingness or inability of parent or caregiver to fulfill the requirements of the study. * females of childbearing potential who are not practicing an effective means of birth control.
emr outcomes: anxiety and depression in epilepsy

Conditions: Quality of Life; Anxiety; Depression; Epilepsy

Summary: the purpose of this research is to find out how people with epilepsy and possible symptoms of anxiety or depression are doing for 6 months after a regular epilepsy clinic visit. participants in this study will complete questionnaires either by phone or via the patient portal.

this is a study among n=30 individuals with epilepsy and high or borderline anxiety or depression symptoms receiving usual care at the wake forest comprehensive epilepsy center. participants are randomized to one of two outcome assessment methods \[electronic medical record (emr)-based-interventional method vs. telephone-based-standard method\] for collecting quality of life, anxiety and depression outcomes at 3 and 6 months, under usual care management. the primary aim of the study is to assess feasibility of emr-based outcome assessment by measuring 6-month retention.

Eligibility criteria:
inclusion criteria: * age 18 or older * completed electronic questionnaires independently in clinic * epilepsy diagnosis (clinician impression or eeg-based) * borderline or high anxiety or depression symptoms at baseline * gad-7 score \> 7 (anxiety) * nddi-e score \> 13 (depression) exclusion criteria: * passive suicidal ideation (nddi-e item 4 score of 3 or 4) * age \<18 years

Keywords: electronic medical record emr patient outcomes
impact of providing high protein bar to dialysis patients with low serum albumin

Conditions: End Stage Renal Disease; Hypoalbuminemia; Malnutrition

Summary: this study is to evaluate the impact of providing high protein supplementation in the form of a medical food bar containing 20grams of protein eath to hypoalbuminemic dialysis patients.


Eligibility criteria:
inclusion criteria: * subjects with esrd undergoing center hemodialysis or peritoneal dialysis for more than 90 days. * 18 years of age or older. * must have a reasonable expectation of remaining on treatment for at least 3 months. * must have an average serum albumin of \<3.5 g/dl over the three months prior to entry into the study. * must be able to understand and sign the informed consent. * must be willing and able to participate in nutrition interviews for determination of nutrient intake from conventional foods. exclusion criteria: * allergy to protein, milk, nuts or wheat. * documented ongoing acute infection or inflammatory process including treatment with antibiotics within a two week time of study entry. * severe acidosis defined as pre-dialysis serum bicarbonate levels of \<15 meq/l. * presence of conditions that would affect normal response to repletion of protein and calories, such as gastrointestinal disorders including inflammatory bowel disease. * hospitalization for an infectious condition within 4 weeks prior to study entry. * planned surgery within the three month study period including planned kidney transplantation.

Keywords: malnutrition hypoalbuminemia dietary supplements hemodialysis peritoneal dialysis
latent viral infection of lymphoid cells in idiopathic nephrotic syndrome

Conditions: NEPHROSIS, LIPOID

Summary: the primary purpose of the study is to evaluate the association of a latent infection of lymphoid cells during the first manifestation of steroid sensitive nephrite syndrome. the thirty nine units of general pediatrics and pediatric nephrite covering the parisian area will participate to the study. we speculate that hybridization of the genome, or a part of the genome, of a virus in lymphoid cells is responsible specific changes of genes expression, leading to the development of the disease.

an additional blood volume will be sampled in patients and controls during a scheduled biological check-up for the initial disease and viral genome of ebv, cmv, hhv6, hhv7 as well as adenovirus will be searched for using pcr reaction in total blood dna extract. the frequency of a latent hybridization of virus genome within human genome will be compared between patients with steroid sensitive nephrotic syndrome and controls matched for age and sex. secondary studies will include a comparison of steroid dependency in nephrotic patients according to the occurence of a latent viral hybridization, the epidemiology of idiopathic nephrotic syndrome in the parisian area and a pharmacogenetic analysis of steroid sensitivity and dependency. if necessary, the chromosomal localization of viral hybridization will be studied with fluorescence in situ hybridization using specific probes.

Eligibility criteria:
inclusion criteria: * proteinuria over 0.25 g/mmol of creatinine with hypoalbuminemia below 30g/l for the case * no history of renal disease * normal c3 and negativity for hepatitis b and c exclusion criteria: * no medical insurance * inclusion in another study

Keywords: latent viral infection genome hybridization herpes virus adenovirus
sleep extension to improve sleep efficiency and qol in hf with preserved ejection fraction: the sleep-hf pilot study

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: nearly one-third of us adults have poor sleep quality. sleep quality refers to sleep efficiency, sleep latency, sleep duration, wake after sleep onset, and movement during the night. specifically, sleep efficiency (se) measures how well an individual utilizes their time in bed for restorative sleep and it highly depends on actual sleep duration. reduced se is associated with a greater risk for heart failure (hf), which affects \~6.7 million adults in the us alone. hf with preserved ejection fraction (hfpef) accounts for about half of all hf diagnoses and is associated with poor prognosis (30-50% 5-year mortality from diagnosis) and severely reduced quality of life (qol). long-term goal for the investigators is to identify sleep modulation as a potential therapeutic target to improve qol in hfpef, with poor se being present in \~60% of patients with hfpef. the study is aimed to see if the sleep modulation is feasible and modulating sleep can improve the qol and functional capacity along with the reduction of inflammation among subjects with hfpef.

the investigators plan a 2-week single-arm open-label feasibility study in 17 subjects with hfpef with a 1-week run-in phase (3 weeks total duration) with a sleep extension intervention combined with sleep hygiene training to improve se in patients with symptomatic hfpef. the investigator's primary endpoint is to increase sleep duration and efficiency with this intervention.

Eligibility criteria:
inclusion criteria: * confirmed clinical diagnosis of stable hf (nyha class ii-iii) * left ventricular ejection fraction\>50% documented in the prior 12 months * aged ≥18 years * habitual reported sleep duration ≤7 hours * sleep efficiency \<85% measured during the 1-week run-in phase exclusion criteria: * concomitant conditions that can limit physical activity * severe debilitating diseases (ischemic heart disease. angina, arterial fibrillation, moderate to severe valvular disease) * taking sleep medicine or melatonin irregularly * pregnancy * stage v kidney disease (with dialysis) * shift worker * insomnia * hospitalization within the last 2 months * patients with sleep and circadian disorders * fluid overload * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners

Keywords: sleep efficiency sleep extension heart failure with preserved ejection fraction quality of life
a study of oral minoxidil to treat hair loss in children, teens, and young adults who are cancer survivors

Conditions: Survivors of Childhood Cancer; Alopecia

Summary: this study will test whether minoxidil taken by mouth (oral minoxidil) can improve hair loss caused by cancer treatment in children and young adults. in addition, the researchers will test the safety of oral minoxidil, and see if the study drug causes few or mild side effects in participants. other purposes of this study include looking at whether participants are able to follow their study drug dosing schedules, and how oral minoxidil affects participants' quality of life.


Eligibility criteria:
inclusion criteria: * patients must have been diagnosed with cancer before the age of 17. * they must have completed either systemic or radiation therapy (cytotoxic chemotherapy and external beam radiation therapy) for their cancer at least 1 year prior to study entry. * they must be between 6-18 years old at the time of enrollment. * they must have a clinical diagnosis of persistent or late alopecia for \>6 months and that is definitely, probably, or possibly related to prior chemotherapy and/or radiation. exclusion criteria: * had a history of alopecia prior to systemic or radiation therapy for cancer, or has alopecia unrelated to cancer treatment. * have scalp disorders that preclude the evaluation of alopecia, such as psoriasis * has a known hypersensitivity to minoxidil * concurrent use of other therapies for alopecia * concurrent active anticancer therapies (cytotoxic, targeted, endocrine, immunologic) * history of chronic sclerotic cutaneous gvhd affecting the scalp * active chronic cutaneous gvhd * history of orthostatic or symptomatic hypotension, syncope related to hypotension; systolic less than or equal than 100 (for adults) and 90 (for children) at screening. * pregnancy. * cardiovascular disease that in the opinion of the cardiologist makes the patient unsuitable for therapy * blood pressure less than the 5th percentile or less than 90/50 mmhg for children 10 years or older

Keywords: hair loss minoxidil 23-022
a study of filanesib (arry-520) and carfilzomib in patients with advanced multiple myeloma

Conditions: Advanced Multiple Myeloma

Summary: this is a phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (arry-520). patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. approximately 75 patients from the us will be enrolled in this study.


Eligibility criteria:
key inclusion criteria: * confirmed multiple myeloma with measurable disease. * disease refractory to last myeloma regimen. * patients must have received at least 2 prior treatment regimens, including bortezomib and an imid (e.g., lenalidomide, thalidomide, pomalidomide). induction therapy and stem cell transplant ± maintenance are to be considered as a single regimen. * eastern cooperative oncology group (ecog) performance status of 0, 1 or 2 within 14 days prior to first dose of study treatment. * adequate hematology, liver and renal function laboratory values within 14 days prior to first dose of study treatment. * additional criteria exist. key exclusion criteria: * prior treatment with carfilzomib, filanesib, or any other ksp inhibitor. * past or current plasma cell leukemia. * primary amyloidosis (amyloidosis associated with multiple myeloma is allowed). * poems syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes). * ongoing grade 3 or grade 4 peripheral neuropathy, or grade 2 peripheral neuropathy with pain despite appropriate interventions, within 28 days prior to first dose of study treatment. * autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study treatment. * concomitant malignancies or previous malignancies (other than multiple myeloma) with less than a 2-year disease-free interval at the time of first dose of study treatment. patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or stage 1 prostate cancer are eligible irrespective of the time of diagnosis. * known pulmonary hypertension of any severity. * concurrent cardiac disease that, in the judgment of the investigator, would make the patient inappropriate for study participation. * known positive serology for the human immunodeficiency virus (hiv), active hepatitis b and/or hepatitis c. * acute active infection requiring treatment. * additional criteria exist.